Previous 10 | Next 10 |
James River Group Holdings (JRVR) -23% after stock offering and Q1 earnings release.Fastly (FSLY) -19% on Q1 earnings release.Regional Health Properties (RHE) -15%.Rocket Companies (RKT) -13% on Q1 earnings release.Etsy (ETSY) -11% on Q1 earnings releas...
If you've ever ordered a piping hot pizza to your door, you already know that convenience is king. It's no secret that people are willing to pay for products that make their lives easier or less painful. But does that same principle hold up for products that consumers uniformly expect to be...
Things were looking gloomy for Vaxart (NASDAQ: VXRT) a few months ago. The clinical-stage biotech company reported that its COVID-19 vaccine candidate didn't produce neutralizing antibodies in a phase 1 trial. These antibodies are considered key since their role is to fight infectio...
Should Investors Be Watching These 4 Top Biotech Stocks Now? You can’t deny that 2020 was a banner year for biotech stocks . Sure, they are among the most volatile stocks in the stock market today , but investors have benefitted handsomely from some. Take Novavax ( ...
Shares of Vaxart (NASDAQ: VXRT) climbed on Tuesday after the biotech released promising data from a clinical trial of its oral coronavirus vaccine candidate. As of 3:30 p.m. EDT, Vaxart's stock price was up more than 12%. A phase 1 study showed Vaxart's vaccine to potentiall...
Vaxart (VXRT) shares are up more than 9.3% in late afternoon trading, a day after the stock dropped 26% due to disappointing Q1 earnings and a delay in a phase 2 trial of its oral COVID-19 vaccine candidate.However, shares rose more than 20% after-hours yesterday as the company repo...
Vaxart (NASDAQ: VXRT) , the biotech creating tablet-based vaccines, jumped 78.2% last month according to S&P Global Market Intelligence . The increase recovered some of the ground it lost after Phase 1 data from its COVID-19 vaccine disappointed investors in early February. ...
Vaxart ([[VXRT]] +16.3%) announces that it has enrolled the first subject in a Phase 1b boosting regimen trial of its norovirus vaccine candidate.The Phase 1b study is designed to enroll 30 subjects aged 18 to 55 years old, with endpoints being safety and immunogenicity.Subjects wil...
BioLineRx (BLRX) +62% on positive top-line results from GENESIS phase 3 trial.Cocrystal Pharma (COCP) +40%.Huttig Building Products, Inc. (HBP) +26% on Q1 results.Vaxart (VXRT) +20% as its oral COVID-19 vaccine shows potential to offer promising solution against variants.Precip...
Study will evaluate safety and immunogenicity of multiple distinct dosing regimens of norovirus oral vaccine candidate Norovirus infects 15% of U.S. children under age five every year Study results may inform the COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif., May 0...
News, Short Squeeze, Breakout and More Instantly...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per ...